EGF Receptors and Bladder Cancer Survival
Author Information
Author(s): Memon A A, Sorensen B S, Meldgaard P, Fokdal L, Thykjaer T, Nexo E
Primary Institution: Aarhus University Hospital
Hypothesis
The final outcome of bladder cancer patients may depend on the balance between the expressions of EGF receptors.
Conclusion
High expression of HER3 and/or HER4 protects bladder cancer patients from the negative effects of high HER1 and/or HER2 expression.
Supporting Evidence
- High expression of HER1 with HER3 and HER4 correlates with better prognosis.
- Patients with high HER2 and high HER3 and HER4 have longer survival.
- Expression of HER1 and HER2 alone does not correlate with survival.
Takeaway
This study found that having high levels of certain proteins can help bladder cancer patients live longer, especially when combined with other proteins.
Methodology
Real-time polymerase chain reaction was used to examine mRNA expression of EGF receptors in bladder cancer biopsies.
Potential Biases
Potential biases may arise from the selection of patients and the retrospective nature of the study.
Limitations
The study may not account for all variables affecting survival, and the follow-up period was limited to a median of 38.5 months.
Participant Demographics
{"sex":{"male":69,"female":19},"age":{"median":72,"range":"53–88"},"tumor_stage":{"Ta":21,"T1":18,"T2–T4":49},"tumor_grade":{"Grade I/II":26,"Grade III/IV":62},"tumor_type":{"papillary":38,"solid":37,"mixed":13}}
Statistical Information
P-Value
{"HER1_HER3_HER4":0.0006,"HER2_HER3_HER4":0.0005}
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website